Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity
Authors:
- Paul R. ManganPMPaul R. Mangan
- Linhui Julie SuLSLinhui Julie Su
- Victoria JennyVJVictoria Jenny
- Andrea L. TatumATAndrea L. Tatum
- Caryn PicarilloCPCaryn Picarillo
- Stacey SkalaSSStacey Skala
- Noah DittoNDNoah Ditto
- Zheng LinZLZheng Lin
- XiaoXia YangXYXiaoXia Yang
- Pete Z. CotterPCPete Z. Cotter
- David J. ShusterDSDavid J. Shuster
- Yunling SongYSYunling Song
- 1 August 2015
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 354 (2) , 152-165
Abstract
Therapies targeting either interleukin (IL)-23 or IL-17 have shown promise in treating T helper 17 (Th17)–driven autoimmune diseases. Although IL-23 is a critical driver of IL-17, recognition of nonredundant and independent functions of IL-23 and IL-17 has prompted the notion that dual inhibition of both IL-23 and IL-17 could offer even greater efficacy for treating autoimmune diseases relative to targeting either cytokine alone. To test this hypothesis, we generated selective inhibitors of IL-23 and IL-17 and tested the effect of either treatment alone compared with their combination in vitro and in vivo. In vitro, using a novel culture system of murine Th17 cells and NIH/3T3 fibroblasts, we showed that inhibition of both IL-23 and IL-17 completely suppressed IL-23–dependent IL-22 production from Th17 cells and cooperatively blocked IL-17–dependent IL-6 secretion from the NIH/3T3 cells to levels below either inhibitor alone. In vivo, in the imiquimod induced skin inflammation model, and in the myelin oligodendrocyte glycoprotein peptide–induced experimental autoimmune encephalomyelitis model, we demonstrated that dual inhibition of IL-17 and IL-23 was more efficacious in reducing disease than targeting either cytokine alone. Together, these data support the hypothesis that neutralization of both IL-23 and IL-17 may provide enhanced benefit against Th17 mediated autoimmunity and provide a basis for a therapeutic strategy aimed at dual targeting IL-23 and IL-17.Keywords
This publication has 60 references indexed in Scilit:
- The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSFNature Immunology, 2011
- Effects of Early IL-17A Neutralization on Disease Induction in a Primate Model of Experimental Autoimmune EncephalomyelitisJournal of Neuroimmune Pharmacology, 2010
- Structure and signalling in the IL-17 receptor familyNature Reviews Immunology, 2009
- Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathwaysBritish Journal of Dermatology, 2008
- IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibitionJournal of Experimental Medicine, 2008
- The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγtNature Immunology, 2008
- Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector categoryJournal of Experimental Medicine, 2008
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007
- Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesJournal of Experimental Medicine, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006